Ozempic and Wegovy, the diabetes and weight-loss drugs, have soared to celebrity status in the U.S. But Novo Nordisk, the Danish company behind them, can’t make enough of them. The New York Times reporter Eshe Nelson went to the drugmaker’s headquarters to see how the company is transforming to deal with the global fame and demand.
